Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombin and antithrombotics

J W Fenton1, F A Ofosu, D V Brezniak

  • 1New York State Department of Health, Albany 12201, USA.

Seminars in Thrombosis and Hemostasis
|May 14, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Management of bleeding disorders: basic science.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Recommendations on biosimilar low-molecular-weight heparins.

Journal of thrombosis and haemostasis : JTH·2009
Same author

Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism.

Thrombosis research·2008
Same author

Statins and thrombin.

Current drug targets. Cardiovascular & haematological disorders·2005
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

Seminars in thrombosis and hemostasis·2026
Same journal

Pediatric Pulmonary Infarction and Infarction-Like Pulmonary Injury: An Etiology-Oriented Narrative Review.

Seminars in thrombosis and hemostasis·2026
Same journal

Comparison of the Coagulation Profile Following Treatment of Major Surgical Haemorrhage with Fresh Frozen Plasma or Fibrinogen Concentrate.

Seminars in thrombosis and hemostasis·2026
See all related articles

Thrombin plays crucial roles in blood clotting, healing, and various diseases. Its unique self-generation makes thrombin a key therapeutic target for antithrombotic interventions.

Area of Science:

  • Biochemistry
  • Physiology
  • Pathology

Background:

  • Thrombin is a key enzyme in hemostasis, regulating blood clotting, clot lysis, and tissue repair.
  • It influences processes like inflammation, cell recruitment, mitogenesis, and angiogenesis.
  • Thrombin is implicated in numerous pathological conditions, including thrombosis, cancer metastasis, and neurodegenerative diseases.

Purpose of the Study:

  • To highlight the multifaceted roles of thrombin in both physiological and pathological processes.
  • To emphasize thrombin's significance as a therapeutic target due to its critical functions and self-generation.
  • To introduce current antithrombotic therapeutic strategies targeting thrombin.

Main Methods:

  • Review of existing literature on thrombin's functions and involvement in diseases.

Related Experiment Videos

  • Analysis of thrombin's unique feedback mechanisms and cellular activation pathways.
  • Examination of therapeutic inhibitors of thrombin.

    • Main Results:

    • Thrombin is essential for normal hemostasis and wound healing.
    • Dysregulation of thrombin contributes to major diseases like thrombosis, cancer, and Alzheimer's disease.
    • Thrombin's self-amplifying nature makes it a critical factor in disease progression.

    Conclusions:

    • Thrombin is a central mediator in numerous biological processes and disease states.
    • Targeting thrombin offers a promising therapeutic strategy for antithrombotic intervention.
    • Inhibitors like Argatroban and Bivalirudin represent advancements in thrombin-directed therapies.